TY - JOUR
T1 - Structurally Simple, Readily Available Peptidomimetic 1-Benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1 H)-one Exhibited Efficient Cardioprotection in a Myocardial Ischemia (MI) Mouse Model
AU - Trifonov, Lena
AU - Nudelman, Vadim
AU - Zhenin, Michael
AU - Matsree, Erez
AU - Afri, Michal
AU - Schmerling, Bruria
AU - Cohen, Guy
AU - Jozwiak, Krzysztof
AU - Weitman, Michal
AU - Korshin, Edward
AU - Senderowitz, Hanoch
AU - Shainberg, Asher
AU - Hochhauser, Edith
AU - Gruzman, Arie
N1 - Publisher Copyright:
Copyright © 2018 American Chemical Society.
PY - 2018/12/27
Y1 - 2018/12/27
N2 - TLR4, a member of the Toll-like receptor (TLR) family, serves as a pattern recognition receptor in the innate immune response to microbial pathogens. TLR4 also regulates the inflammatory reaction to ischemic injury in the heart. The TRIF-related adaptor molecule (TRAM) is an adapter that recruits the Toll/interleukin 1 receptor (TIR) domain, which contains adapter-inducing IFN-β (TRIF), to activate TLR4, following TRIF-dependent cytokine gene transcription. On the basis of a known TRAM-derived decoy peptide, 10 of its peptidomimetics were synthesized. One of them, 1-benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one (21), exhibited high potency and efficacy in vitro. In vitro results and in silico analysis provided evidence for the possible direct interaction of 21 with the TLR4 complex. Administered in mice, 21 was able to block the pathophysiological manifestation of MI, restoring the concomitant tissue damage, with a 100% survival rate. Thus, inhibition of TLR4-mediated inflammation in postischemic myocardium could be used as an approach for developing cardioprotective drugs.
AB - TLR4, a member of the Toll-like receptor (TLR) family, serves as a pattern recognition receptor in the innate immune response to microbial pathogens. TLR4 also regulates the inflammatory reaction to ischemic injury in the heart. The TRIF-related adaptor molecule (TRAM) is an adapter that recruits the Toll/interleukin 1 receptor (TIR) domain, which contains adapter-inducing IFN-β (TRIF), to activate TLR4, following TRIF-dependent cytokine gene transcription. On the basis of a known TRAM-derived decoy peptide, 10 of its peptidomimetics were synthesized. One of them, 1-benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one (21), exhibited high potency and efficacy in vitro. In vitro results and in silico analysis provided evidence for the possible direct interaction of 21 with the TLR4 complex. Administered in mice, 21 was able to block the pathophysiological manifestation of MI, restoring the concomitant tissue damage, with a 100% survival rate. Thus, inhibition of TLR4-mediated inflammation in postischemic myocardium could be used as an approach for developing cardioprotective drugs.
UR - http://www.scopus.com/inward/record.url?scp=85058558782&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.8b01471
DO - 10.1021/acs.jmedchem.8b01471
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30507195
SN - 0022-2623
VL - 61
SP - 11309
EP - 11326
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 24
ER -